Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02245243 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment
A Phase 1 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02245243 is a Phase 1 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT02245243, a Phase 1 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetic profile, safety, and tolerability of a single intravenous (IV) dose of delafloxacin in normal healthy subjects and subjects with mild, moderate, or severe hepatic impairment.
Interventions
- DRUG Delafloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02245243
The ClinicalTrials.gov registry entry for NCT02245243 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Delafloxacin is the first listed.
NCT02245243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02245243 about?
NCT02245243 is a clinical study titled "Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment". The purpose of this study is to evaluate the pharmacokinetic profile, safety, and tolerability of a single intravenous (IV) dose of delafloxacin in normal healthy subjects and subjects with mild, moderate, or severe hepatic impairment.
What is the current status of trial NCT02245243?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02245243?
The interventions under investigation include: Delafloxacin (DRUG).
Who is sponsoring clinical trial NCT02245243?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.